Indian Peptide Drugs Market
The Indian peptide drugs market is expected to reach USD 883.0 million by 2022 from USD 381.8 million in 2016, at a CAGR of 15.0%.
Increasing prevalence of chronic diseases and favorable government policies for the pharmaceutical sector are driving the growth of this market.
The Indian peptide drugs market is consolidated in nature with a large number of players. The Indian peptide drugs market is dominated by Abbott Laboratories (US), Sanofi S.A. (France), Eli Lilly and Company (US), Cipla Limited (India), and Biocon Limited (India), which together held a share of 68.2% in 2016. Other companies in the Indian peptide drugs market are Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
Download a PDF Brochure:-
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
Indian anticoagulant drugs Market
The Indian anticoagulant drugs market is expected to reach USD 170.26 million by 2022 from USD 127.82 million in 2016, at a CAGR of 4.9%.
The growing incidence of coagulation disorders and government support for pharmaceutical companies are driving the growth of this market.
The Indian anticoagulant drugs market is also consolidated in nature. The Indian anticoagulant drugs market is dominated by Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), and Lupin Ltd. (India), which together held a share of 68.6% of the market in 2016. Other players in this market include Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India). These companies accounted for a combined share of 31.4% of the Indian anticoagulant drugs market in 2016.
Request Sample Pages:-
https://www.marketsandmarkets.com/requestsampleNew.asp?id=77044734
